VEFLOX-D EYE DROPS

Ofloxacin 0.3% + Dexamethasone 0.1%
Sterile ophthalmic preparation | 5 mL

COMPOSITION

Each 1 mL contains:
Ofloxacin 3 mg (0.3% w/v)
Dexamethasone 1 mg (0.1% w/v), subject to confirmation of the dexamethasone salt and label-equivalent basis. Other ingredients according to the approved formulation.

THERAPEUTIC CLASS

Ophthalmic fluoroquinolone antibiotic (ofloxacin) combined with an ophthalmic corticosteroid (dexamethasone). Primary segment: ophthalmology.

PHARMACOLOGY

Ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with bacterial DNA replication. Dexamethasone suppresses inflammatory responses, reducing redness, swelling and irritation. Steroids can mask or worsen certain infections.

INDICATIONS

Steroid-responsive inflammatory conditions of the anterior eye where susceptible bacterial infection is present or there is a significant risk of bacterial infection, when a combined antibiotic and corticosteroid is appropriate. Use only for indications approved for Veflox-D and under ophthalmic supervision.

DOSAGE AND ADMINISTRATION

For topical ophthalmic use only. A regimen described for a marketed ofloxacin 0.3% / dexamethasone 0.1% combination is **1–2 drops in the affected eye(s) every 2–4 hours initially, then four times daily**, as clinically directed. Dose, frequency and treatment duration must follow the approved Veflox-D label; reassess promptly if there is no improvement. Do not use the intensive dosing schedules for ofloxacin-only corneal ulcer treatment as a routine combination regimen.

METHOD OF USE

Wash hands. Tilt head back, gently pull lower eyelid and instil the prescribed drops without touching the dropper tip to the eye or other surfaces. Close eye gently and press at the inner corner for about one minute. Replace cap immediately. Separate other ophthalmic drops by at least 5 minutes unless otherwise instructed. Shake only if the approved Veflox-D formulation is a suspension and its label instructs shaking.

CONTRAINDICATIONS

Hypersensitivity to ofloxacin, other quinolones, dexamethasone or any ingredient. Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella and many other viral corneal/conjunctival diseases; fungal eye infections; and mycobacterial eye infections. Do not use for undiagnosed red eye.

WARNINGS: STEROID RISKS

Prolonged corticosteroid use can raise intraocular pressure, cause glaucoma with optic nerve damage, posterior subcapsular cataract, delayed healing and corneal or scleral thinning/perforation. Steroids may conceal infection or encourage secondary bacterial, viral or fungal infection. Monitor intraocular pressure if treatment is prolonged (commonly 10 days or more).

WARNINGS: INFECTION AND ALLERGY

Stop treatment and seek urgent care for severe allergic reaction, facial swelling, difficulty breathing or extensive rash. Prolonged antibiotic use may encourage nonsusceptible organisms. Persistent corneal ulceration warrants assessment for fungal infection. Severe pain, photophobia, reduced vision or worsening redness requires prompt ophthalmic evaluation.

PRECAUTIONS

Use with caution in patients with glaucoma, ocular hypertension, corneal thinning or previous herpetic keratitis. Steroid-containing drops should not be used without adequate clinical assessment after ocular surgery or trauma. Avoid contact lenses during active ocular infection. Do not share the bottle.

DRUG INTERACTIONS

Clinically significant systemic interactions are unlikely with correct topical use, but systemic absorption is possible. Inform the prescriber about other ophthalmic drugs and corticosteroids. Separate topical eye medicines to prevent washout.

PREGNANCY AND LACTATION

Use during pregnancy or breastfeeding only if the clinician judges the expected benefit to outweigh potential risk. Adequate data for this exact ophthalmic combination are limited. Nasolacrimal occlusion may reduce systemic exposure.

PAEDIATRIC USE

Safety and efficacy for this exact combination and age group must be established by the locally approved labeling. Use in children only on an ophthalmologist's advice.

ADVERSE REACTIONS

Transient burning, stinging, irritation, tearing, blurred vision, itching or redness may occur. Potential serious effects include allergic reactions, increased intraocular pressure, cataract, delayed healing, corneal complications and secondary infection.

OVERDOSAGE

Excess topical dosing may increase local irritation. Rinse excess solution from the eye with clean lukewarm water if necessary. Accidental ingestion, especially by a child, requires medical advice. Treatment is supportive.

STORAGE

Store as directed by the approved Veflox-D label. Keep container tightly closed, protect from contamination and keep out of reach of children. Confirm the labeled temperature range and discard period after first opening before printing.

PRESENTATION

Veflox-D Eye Drops: Ofloxacin 0.3% + Dexamethasone 0.1%, sterile ophthalmic preparation in a **5 mL** bottle.

MANUFACTURED BY

Vega Pharmaceuticals (Pvt.) Ltd.